Conference Coverage

Exercise may help stall MS disability and progression


 

FROM ECTRIMS 2021

Next steps

Challenges remain for the field. “We still need to figure out how long-term adherence is best secured in these patients, and then we really need to look further into how to provide exercise in the best possible way in severe and elderly patients,” said Dr. Dalgas.

During the Q&A session following the presentation, Dr. Dalgas was asked for advice on how to get a patient with MS started with exercise. “We normally recommend that people should find a physical therapist or sports scientist who has expertise in this field to help with getting started. If you start out wrong you can get into problems, so having the right expertise at hand is a good way to start. Then shortly afterward they will be more independent to do the exercise,” said Dr. Dalgas.

Alan Thompson, MD, who moderated the session, brought up the concept of cognitive reserve in MS, which posits that positive life experience builds up the capacity and efficiency of neural networks, which in turn act as a sort of buffer against later cognitive decline due to aging and illness. “Can you build up your exercises in a way that has a meaningful impact in delaying the onset of confirmed disability or progression?” asked Dr. Thompson, professor of clinical neurology and neurorehabilitation at University College London.

Dr. Dalgas said that there are studies that suggest this may be true, with MS diagnoses occurring later in patients who are physically active. “You can interpret that as some kind of delayed onset of the disease.”

For more information, Dr. Dalgas suggested recently published recommendations for exercise in MS patients.

Dr. Dalgas disclosed ties with Biogen Idec, Merck Serono, Sanofi Aventis, Almirall, Novartis, Bayer Schering, and Sanofi Genzyme. Dr. Thompson has no relevant financial disclosures.

Pages

Recommended Reading

Quality of Life, Diagnosis, and/or Therapeutics in Pediatric MS
MDedge Neurology
COVID-19 vaccination in MS: Lower response on certain medications
MDedge Neurology
Melatonin improves sleep in MS
MDedge Neurology
Cortical lesions predict risk for secondary progressive MS
MDedge Neurology
In MS, baseline cortical lesions predict cognitive decline
MDedge Neurology
Ublituximab improves functional MS score: New ULTIMATE analysis
MDedge Neurology
The Barcelona baseline risk score may predict long-term MS course
MDedge Neurology
ECTRIMS/EAN statement on COVID-19 vaccination in patients with MS
MDedge Neurology
Rituximab more effective than other MS treatments?
MDedge Neurology
MS and (non-COVID) vaccinations: consensus recommendations
MDedge Neurology